Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Sangamo BioSciences (SGMO) PT Raised to $33 at Jefferies
February 23, 2018 8:58 AM ESTJefferies raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $33.00 (from $18.00) while maintaining a Buy rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
February 23, 2018 7:24 AM ESTJPMorgan raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $35.00 (from $11.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $32 at Piper Jaffray, Remains Positive Citing Broadening Platform
February 22, 2018 4:26 PM ESTPiper Jaffray raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $32.00 (from $25.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $39 at Wells Fargo
February 22, 2018 12:23 PM ESTWells Fargo raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $39.00 (from $30.00) while maintaining a Outperform rating.
The analyst likes the company's competitive advantage in gene-editing, which is attributed to years of experience with single loci targeting and suspects it should be... More
Sangamo BioSciences (SGMO) PT Raised to $30 at Barclays
February 22, 2018 11:56 AM ESTBarclays raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $30.00 (from $20.00) while maintaining a Overweight rating.
Analyst Gena Wang ups the price target to reflect technology capabilities at the company and progress in clinical programs. The analyst says the with... More
